Journal of the Korean Magnetic Resonance Society (한국자기공명학회논문지)

Korean Magnetic Resonance Society (한국자기공명학회)
권호 표지
DOI QR코드

DOI QR Code

Structural Characterization of the C-terminal tail of EBV LMP2A

  • Gaurab Subedi (College of Pharmacy and Gachon Institute of Pharmaceutical Sciences, Gachon University) ;
  • Sung Jean Park (College of Pharmacy and Gachon Institute of Pharmaceutical Sciences, Gachon University)
  • Received : 2024.11.14
  • Accepted : 2024.11.28
  • Published : 2024.12.20
Download PDF
⟨ Previous Next ⟩

Abstract

Epstein-Barr virus (EBV) Latent Membrane Protein 2A (LMP2A) is a transmembrane protein essential for viral latency and immune evasion, structured with distinct functional domains. The N-terminal domain modulates B-cell receptor signaling, while the transmembrane and C-terminal regions help anchor the protein and facilitate additional interactions within host cells. This study characterizes the LMP2A C-terminal domain (CTD) structure under various conditions using CD spectroscopy and NMR. The 29-residue C-tail sequence contains key residues that impact stability. CD analysis shows that, while disordered at neutral pH and in water, helicity is slightly enhanced under acidic conditions and membrane-mimicking environments, with DTT influencing stability through oxidation state effects. NMR structural analysis in DPC micelles reveals a well-converged helical structure extending from residues R471 to E486, closely matching AlphaFold predictions. The data highlight the CTD's structural plasticity and suggest roles for cysteines and hydrophobic clusters in stabilizing the peptide in membrane-like settings.

Keywords

Acknowledgement

This work was supported by the Gachon University research fund of 2022 (GCU-20220903001).This research was also supported by the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science, and Technology (2020R1A6A1A0304370812).

References

  1. S. J. Park, M. D. Seo, S. K. Lee, M. Ikeda, R. Longnecker, and B. J. Lee, Protein Expr. Purif. 41, 9 (2005) https://doi.org/10.1016/j.pep.2004.07.006
  2. K. Fish, F. Comoglio, A. L. Shaffer et al., Proc. Natl. Acad. Sci. U. S. A. 117, 26318 (2020) https://doi.org/10.1073/pnas.2007946117
  3. R. P. Sora, M. Ikeda, and R. Longnecker, mBio. 10, e00548-19 (2019)
  4. M. D. Seo, S. J. Park, H. J. Kim, and B. J. Lee, FEBS Lett. 581, 65 (2007) https://doi.org/10.1016/j.febslet.2006.11.078
  5. J. Y. Shin, J. O. Kim, S. K. Lee, H. S. Chae, and J. H. Kang, BMC Cancer 13, 425 (2010)
  6. C. Rancan, L. Schirrmann, C. Hüls, R. Zeidler, and A. Moosmann, PLoS Pathog. 11, e1004906 (2015) https://doi.org/10.1371/journal.ppat.1004906
  7. C. Yu, X. Zhang, J. Wang, H. Song, W. Liu, and B. Luo, Virus Res. 322, 198947 (2022) https://doi.org/10.1016/j.virusres.2022.198947
  8. Y. Liao, J. Yan, N. R. Beri, L. Giulino-Roth, E. Cesarman, and B. E. Gewurz, PLoS Pathog. 29, e1011939 (2024) https://doi.org/10.1371/journal.ppat.1011939
  9. M. D. Seo, S. H. Seok, J. H. Kim, J. W. Choi, S. J. Park, and B. J. Lee, Life (Basel) 11, 379 (2021) https://doi.org/10.3390/life11050379
  10. M. Fukuda and Y. Kawaguchi, J. Virol. 88, 5189 (2014) https://doi.org/10.1128/JVI.03714-13
  11. O. Cen and R. Longnecker, Curr. Top Microbiol. Immunol. 391, 151 (2015) https://doi.org/10.1007/978-3-319-22834-1_5
  12. T. Zhong and S. J. Park, Drug Targets and Therapeutics 3, 111 (2024) https://doi.org/10.58502/DTT.24.0010
  13. G. Subedi and S. J. Park, Drug Targets and Therapeutics 2, 71 (2023) https://doi.org/10.58502/DTT.23.0013
  14. J.-S. Hyun and S. J. Park. J. Korean Magn. Reson.Soc. 27, 23 (2023)
  15. S. J. Park, J. Korean Magn. Reson.Soc. 26, 24 (2022)
  16. A. T. Brünger, P. D. Adams, G. M. Clore et al., Acta Crystallogr. D Biol. Crystallogr. 54, 905 (1998) https://doi.org/10.1107/S0907444998003254
  17. M. Mirdita, K. Schütze, Y. Moriwaki, L. Heo, S. Ovchinnikov, and M. Steinegger, Nat. Methods 19, 679 (2022) https://doi.org/10.1038/s41592-022-01488-1